Living with paroxysmal nocturnal hemoglobinuria (PNH) isn’t just about managing what’s happening today; it’s also about facing what could happen tomorrow. As much as I try to live in the moment, I’d be lying if I said the potential complications of PNH don’t cross my mind. The truth is,…
Read more
Novo Nordisk has entered a license agreement with Omeros for the development and commercialization of zaltenibart (OMS906), an experimental treatment for paroxysmal nocturnal hemoglobinuria (PNH). The deal, expected to be close by year-end 2025, will give Novo Nordisk exclusive global rights for zaltenibart in all indications. Once finalized,…
People switching between treatments for paroxysmal nocturnal hemoglobinuria (PNH) may develop transient immune complex reactions (TICRs) — a type of inflammatory reaction — but these are usually not serious and manageable, a new analysis of more than 200 people finds. The analysis covered people who switched from Soliris…
Living with paroxysmal nocturnal hemoglobinuria (PNH) since 2017 has taught me that finding the right physician is as important as the treatment itself. Because PNH is rare, I need a doctor who is more than a medical expert — they must also be a partner in this…
Get regular updates delivered to your inbox.
